SG11202011242SA - SELECTIVE TREG STIMULATOR RUR20kD-IL-2 AND RELATED COMPOSITIONS - Google Patents
SELECTIVE TREG STIMULATOR RUR20kD-IL-2 AND RELATED COMPOSITIONSInfo
- Publication number
- SG11202011242SA SG11202011242SA SG11202011242SA SG11202011242SA SG11202011242SA SG 11202011242S A SG11202011242S A SG 11202011242SA SG 11202011242S A SG11202011242S A SG 11202011242SA SG 11202011242S A SG11202011242S A SG 11202011242SA SG 11202011242S A SG11202011242S A SG 11202011242SA
- Authority
- SG
- Singapore
- Prior art keywords
- rur20kd
- related compositions
- selective treg
- treg stimulator
- stimulator
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Inorganic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862674244P | 2018-05-21 | 2018-05-21 | |
PCT/US2019/033100 WO2019226538A1 (en) | 2018-05-21 | 2019-05-20 | SELECTIVE TREG STIMULATOR RUR20kD-IL-2 AND RELATED COMPOSITIONS |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202011242SA true SG11202011242SA (en) | 2020-12-30 |
Family
ID=67002369
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202011242SA SG11202011242SA (en) | 2018-05-21 | 2019-05-20 | SELECTIVE TREG STIMULATOR RUR20kD-IL-2 AND RELATED COMPOSITIONS |
Country Status (19)
Country | Link |
---|---|
US (1) | US20210205413A1 (es) |
EP (1) | EP3796940A1 (es) |
JP (3) | JP7235772B2 (es) |
CN (1) | CN112399859A (es) |
AU (2) | AU2019274409B2 (es) |
BR (1) | BR112020021564A2 (es) |
CA (1) | CA3100204A1 (es) |
CL (1) | CL2020003008A1 (es) |
CO (1) | CO2020014510A2 (es) |
CR (1) | CR20200546A (es) |
DO (1) | DOP2020000212A (es) |
EA (1) | EA202092489A1 (es) |
EC (1) | ECSP20074392A (es) |
IL (2) | IL312646A (es) |
JO (1) | JOP20200290A1 (es) |
PE (1) | PE20211307A1 (es) |
PH (1) | PH12020551976A1 (es) |
SG (1) | SG11202011242SA (es) |
WO (1) | WO2019226538A1 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115315436A (zh) | 2020-01-10 | 2022-11-08 | 明峰治疗股份公司 | 修饰的il-2多肽及其用途 |
CN113121670B (zh) * | 2020-01-15 | 2022-11-22 | 天津键凯科技有限公司 | 二取代peg化白细胞介素2及其制备方法、应用 |
WO2021143572A1 (zh) * | 2020-01-15 | 2021-07-22 | 天津键凯科技有限公司 | 一种制备结合位点可控的peg化生物分子的方法 |
JP2021143142A (ja) * | 2020-03-11 | 2021-09-24 | 花王株式会社 | 制御性t細胞誘導剤 |
WO2021236474A1 (en) * | 2020-05-22 | 2021-11-25 | Merck Sharp & Dohme Corp. | Novel processes for preparing conjugates of the il-2 protein |
TW202228784A (zh) | 2020-09-23 | 2022-08-01 | 奧地利商艾柏力維亞生技有限公司 | 用以於一患者中螯合非預期的抗peg抗體的化合物 |
WO2022109477A1 (en) * | 2020-11-23 | 2022-05-27 | University Of Florida Research Foundation, Incorporated | Use of insulin-like growth factors with gamma-chain cytokines to induce homeostatic proliferation of lymphocytes |
KR20240123817A (ko) | 2021-12-14 | 2024-08-14 | 넥타르 테라퓨틱스 | 선택적 TREG 자극제 RUR20kD-IL-2를 위한 투여 계획 및 관련 조성물 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4401756A (en) | 1981-04-14 | 1983-08-30 | Immunex Corporation | Process for preparing human interleukin 2 |
US4569790A (en) | 1984-03-28 | 1986-02-11 | Cetus Corporation | Process for recovering microbially produced interleukin-2 and purified recombinant interleukin-2 compositions |
US5116943A (en) | 1985-01-18 | 1992-05-26 | Cetus Corporation | Oxidation-resistant muteins of Il-2 and other protein |
US5206344A (en) | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
US5153310A (en) | 1989-02-28 | 1992-10-06 | Du Pont Merck Pharmaceutical Company | Il-2 analogs containing n-linked glycosylation sites |
US5635597A (en) | 1994-05-27 | 1997-06-03 | Affymax Technologies, N.V. | Peptides that bind IL-2 receptors |
US6168785B1 (en) | 1998-07-16 | 2001-01-02 | Institut Pasteur | Biological applications of new peptides of IL-2 and derivatives and use as therapeutic agents |
FR2826365B1 (fr) | 2001-06-20 | 2003-09-26 | Oreal | Compositions cosmetiques photoprotectrices contenant des derives amides, sulfonamides ou carbamates aromatiques d'acrylonitrile et nouveaux derives amides, sulfonamides ou carbamates d'acrylonitrile |
PT2644206T (pt) | 2003-05-23 | 2019-07-10 | Nektar Therapeutics | Derivados de peg contendo duas cadeias de peg |
WO2005007121A2 (en) | 2003-07-18 | 2005-01-27 | Massachusetts Institute Of Technology | Mutant interleukin-2(il-2) polypeptides |
US7567215B1 (en) | 2007-10-23 | 2009-07-28 | The United States Of America As Represented By The Secretary Of The Navy | Portable and inflatable antenna device |
RS61854B1 (sr) * | 2010-11-12 | 2021-06-30 | Nektar Therapeutics | Konjugati il-2 dela i polimera |
EP3766513A1 (en) * | 2011-03-11 | 2021-01-20 | Assistance Publique Hôpitaux de Paris | Use of low dosage il-2 for treating vasculitis |
EP3431096A4 (en) * | 2016-03-16 | 2020-01-15 | Xie, Yanhui | GLUCOCORTICOID COMBINED WITH INTERLEUKIN-2 MODIFIED BY POLYETHYLENE GLYCOL TO TREAT RESPIRATORY DISEASE |
-
2019
- 2019-05-20 EA EA202092489A patent/EA202092489A1/ru unknown
- 2019-05-20 AU AU2019274409A patent/AU2019274409B2/en active Active
- 2019-05-20 IL IL312646A patent/IL312646A/en unknown
- 2019-05-20 CN CN201980034052.1A patent/CN112399859A/zh active Pending
- 2019-05-20 PE PE2020001854A patent/PE20211307A1/es unknown
- 2019-05-20 CA CA3100204A patent/CA3100204A1/en active Pending
- 2019-05-20 IL IL278528A patent/IL278528B1/en unknown
- 2019-05-20 US US17/056,050 patent/US20210205413A1/en active Pending
- 2019-05-20 EP EP19732788.5A patent/EP3796940A1/en active Pending
- 2019-05-20 SG SG11202011242SA patent/SG11202011242SA/en unknown
- 2019-05-20 WO PCT/US2019/033100 patent/WO2019226538A1/en active Application Filing
- 2019-05-20 JO JOP/2020/0290A patent/JOP20200290A1/ar unknown
- 2019-05-20 CR CR20200546A patent/CR20200546A/es unknown
- 2019-05-20 JP JP2020564540A patent/JP7235772B2/ja active Active
- 2019-05-20 BR BR112020021564-3A patent/BR112020021564A2/pt unknown
-
2020
- 2020-11-18 PH PH12020551976A patent/PH12020551976A1/en unknown
- 2020-11-19 DO DO2020000212A patent/DOP2020000212A/es unknown
- 2020-11-19 CL CL2020003008A patent/CL2020003008A1/es unknown
- 2020-11-20 EC ECSENADI202074392A patent/ECSP20074392A/es unknown
- 2020-11-23 CO CONC2020/0014510A patent/CO2020014510A2/es unknown
-
2022
- 2022-10-06 AU AU2022246440A patent/AU2022246440A1/en active Pending
- 2022-12-23 JP JP2022206250A patent/JP2023052053A/ja active Pending
-
2024
- 2024-06-07 JP JP2024092962A patent/JP2024116272A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CR20200546A (es) | 2021-05-18 |
WO2019226538A1 (en) | 2019-11-28 |
PH12020551976A1 (en) | 2021-09-13 |
AU2022246440A1 (en) | 2022-11-03 |
IL312646A (en) | 2024-07-01 |
JP2023052053A (ja) | 2023-04-11 |
JOP20200290A1 (ar) | 2020-11-15 |
CA3100204A1 (en) | 2019-11-28 |
IL278528A (es) | 2021-01-31 |
AU2019274409A1 (en) | 2020-11-12 |
CO2020014510A2 (es) | 2021-03-08 |
US20210205413A1 (en) | 2021-07-08 |
DOP2020000212A (es) | 2021-03-15 |
IL278528B1 (en) | 2024-06-01 |
ECSP20074392A (es) | 2021-03-31 |
JP7235772B2 (ja) | 2023-03-08 |
EA202092489A1 (ru) | 2021-03-16 |
AU2019274409B2 (en) | 2022-07-14 |
CL2020003008A1 (es) | 2021-07-30 |
PE20211307A1 (es) | 2021-07-20 |
CN112399859A (zh) | 2021-02-23 |
JP2024116272A (ja) | 2024-08-27 |
JP2021523922A (ja) | 2021-09-09 |
BR112020021564A2 (pt) | 2021-03-02 |
KR20210002577A (ko) | 2021-01-08 |
EP3796940A1 (en) | 2021-03-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL280134A (en) | Anti-CD112R preparations and methods | |
IL277079A (en) | Cartirin preparations and methods of use | |
SG11202011242SA (en) | SELECTIVE TREG STIMULATOR RUR20kD-IL-2 AND RELATED COMPOSITIONS | |
SG11202105626TA (en) | Oligonucleotide compositions and methods thereof | |
ZA202004678B (en) | Compositions comprising co-selected microbiota and methods for use thereof | |
GB201807325D0 (en) | Compositions and methods | |
SG11202104448WA (en) | Compositions and methods | |
ZA202101362B (en) | Compositions and methods for treating the eye | |
GB2578519B (en) | Compositions and methods and uses relating thereto | |
IL279059A (en) | Methods and preparations for killing spores | |
ZA202101342B (en) | Compositions and methods for treating the eye | |
GB201815402D0 (en) | Compositions and methods and uses relating thereto | |
EP3773654C0 (en) | POLYPHARMACEUTICAL DRUG COMPOSITIONS AND ASSOCIATED METHODS | |
IL290325A (en) | Biopharmaceutical preparations and related methods | |
ZA202004533B (en) | Skin-brightening compositions and methods | |
GB201804163D0 (en) | Uses, compositions and methods | |
GB201819987D0 (en) | Methods and compositions | |
GB201817444D0 (en) | Methods and compositions | |
ZA202101360B (en) | Compositions and methods for treating the eye | |
ZA202101361B (en) | Compositions and methods for treating the eye | |
EP3664773A4 (en) | HAIR TREATMENT COMPOSITIONS AND PROCEDURES | |
ZA202103276B (en) | Bioflavonoid compositions and their use | |
SG11202108262VA (en) | Bacterialcidal methods and compositions | |
EP3903741C0 (en) | BIOLOGICAL COATING AND IMPLANT | |
SG11202008215VA (en) | Flavor and consummable compositions |